心臟即時檢測設備市場按產品類型、最終用戶、技術、樣品類型和應用分類－2025-2032年全球預測

預計到 2032 年，心臟即時檢測設備市場規模將成長 40 億美元，複合年成長率為 12.85%。

關鍵市場統計數據
基準年2024年	15.2億美元
預計年份：2025年	16.9億美元
預測年份 2032	40億美元
複合年成長率 (%)	12.85%

一份簡潔而照護現場心臟診斷指南，為臨床需求、業務重點和策略應用促進因素提供了框架。

床邊心臟診斷設備已成為現代心血管護理的關鍵工具，重塑了臨床醫生檢測和應對急性心臟事件的方式。這些平台可在患者床邊或床邊提供生物標記資訊，縮短診斷時間，並支援快速制定治療決策。對於許多醫療機構而言，縮短急性冠狀動脈症候群和心臟衰竭加重等疾病的診斷時間是臨床工作的重中之重，而床邊診斷解決方案透過提供快速、可操作的檢測結果，並將其整合到急診和住院工作流程中，直接助力實現這一目標。

從營運角度來看，醫院和診所重視那些兼具分析性能、易用性、低維護成本以及與電子健康記錄無縫整合等優勢的儀器。檢測化學和訊號檢測技術的進步提高了靈敏度和特異性，增強了臨床醫生對即時檢測結果的信心。因此，臨床效用、工作流程相容性和整體擁有成本 (TCO) 等因素越來越成為推動儀器應用的重要因素。相關人員在評估對心臟即時檢測技術的策略性投資時，不僅會考慮診斷準確性，還會考慮設備體積、耗材物流、員工培訓需求以及影響長期營運可行性的監管路徑。

綜上所述，這些因素意味著即時檢驗（POC）設備是加速臨床診療和提高系統效率的工具。哪些平台最終能成為急診和門診的標準設備，將取決於製造商和醫療系統能否使產品設計與臨床需求和報銷實際情況相符。

技術進步、臨床工作流程重新設計以及不斷變化的報銷預期如何改變心臟照護現場診斷的採用和效用

由於技術創新、醫療模式的轉變以及人們對快速診斷準確性的日益成長的期望，心臟就地檢驗領域正經歷著顯著的變化。在技​​術方面，檢測組件的小型化、電化學和光學檢測系統的整合以及免疫測量方法的改進，在提高分析性能的同時，也縮短了獲得結果的時間。這些進展拓展了即時偵測的可靠應用場景，使其涵蓋了院前急救和資源有限的診所環境。

同時，醫療服務模式也在不斷演變。急診和心臟監護病房越來越依賴更快速的診斷資訊來優先處理患者並管理床位流動。這些臨床壓力，加上更廣泛的去中心化醫療模式，推動了對功​​能強大的床邊檢測平台的需求，這些平台能夠提供實驗室級別的檢測結果，而無需像中心實驗室那樣耗時。同時，支付方和醫療系統也仔細檢視醫療服務的價值，傾向於那些能夠透過早期療育和減少住院次數來顯著降低後續成本的解決方案。最終，這些因素累積促成了醫療服務從早期試驗階段轉向主流臨床整合的轉變。

監管和報銷框架也在不斷調整，醫療機構正在明確床邊檢測設備的性能預期，而支付方也在完善醫療保險政策以反映臨床證據。因此，能夠證明其產品具有持續的分析有效性、營運韌性和可衡量的臨床影響的製造商，更有可能獲得更高的市場認可。摘要，技術進步、臨床工作流程的重新設計和經濟課責正在共同推動心臟床邊檢測技術在促進更快、更有效率的醫療保健方面發揮變革性作用。

評估2025年關稅主導的供應鏈壓力和策略採購應對措施對設備可用性、採購經濟性和業務連續性的影響

貿易政策的發展，包括計劃於2025年在美國實施的關稅調整，為心臟即時檢測生態系統中的製造商、經銷商和醫療保健採購商帶來了新的考量。這些關稅將影響零件採購、定價策略和供應鏈韌性，促使製造商重新評估其採購佈局，並探索其他製造地和供應商合作關係。為此，許多公司已開始實現供應鏈多元化，以降低對單一國家的風險敞口，並在不影響臨床性能的前提下維持利潤率。

這些關稅主導的壓力也影響分銷經濟。經銷商和醫院採購團隊正在調整合約條款和庫存策略，以應對潛在的成本波動。關稅的影響促使一些供應商加快組裝本地化組裝，並簽訂長期零件契約，以穩定單價並縮短補貨週期。此外，關稅的影響也促使人們更加關注投入成本的細分，提高了供應商和客戶之間的透明度，使他們能夠預測成本調整，而不是被動應對。

從臨床營運角度來看，不斷上升的成本壓力促使醫療系統優先選擇能夠顯著提高工作流程效率並減少後續資源消耗的設備，例如縮短急診停留時間和減少不必要的住院。最終，這迫使相關人員考慮如何在應對經濟變化的同時維持臨床服務能力，在控制成本和持續獲得高品質診斷之間取得平衡，並推動策略性供應鏈規劃。

全面的細分分析，重點在於生物標記選擇、終端使用者工作流程需求、檢測技術、樣本偏好和關鍵心臟應用。

對心臟就地檢驗市場進行細緻的細分，揭示了產品、終端用戶、技術、樣本類型和應用等方面的動態變化，這些因素共同塑造了市場需求和發展重點。產品差異化主要圍繞在生物標記展開，例如腦鈉肽（BNP）、肌酸激酶同工酶（CK-MB）、肌紅蛋白和肌鈣蛋白，其中肌鈣蛋白檢測可進一步細分為肌鈣蛋白I和肌鈣蛋白T。在某些臨床情況下，CK-MB和肌紅蛋白仍然具有效用，因為補充資訊和歷史數據對比在這些情況下具有臨床意義。

終端使用者細分涵蓋診所、診斷實驗室和醫院，其中醫院包括心臟監護病房和急診。急診室優先考慮速度和高效的工作流程，而心臟監護病房則重視連續測量功能以及與連續監測系統的整合。診所和門診中心重視緊湊、低維護的設備，這些設備有助於分診和隨訪，且不會增加實驗室營運成本。採用即時偵測平台的診斷實驗室通常是為了在尖峰時段分流高通量分析儀，或將服務擴展到衛星站點。

技術差異包括比色法、電化學法和免疫檢測法，其中免疫免疫檢測可細分為螢光和側向流動法。比色法在檢測某些分析物時具有簡單性和成本優勢；電化學平台具有小型化和低功耗的優勢；而免疫檢測能提供檢測低豐度心臟生物標記所需的靈敏度。在樣本類型方面，主要考慮血漿、血清和全血。全血樣本無需離心步驟，提高了床邊應用的便利性；而當需要實驗室整合和標準化處理時，血漿和血清樣本則更為理想。按應用領域分類，這些設備主要針對急性冠狀動脈症候群和心臟衰竭等應用場景而開發，每個場景對靈敏度、週轉時間和長期監測的要求各不相同。了解這些細分領域有助於相關人員將產品設計、臨床檢驗和商業化策略與最終用戶的實際營運需求相匹配。

在全球範圍內，區域需求和醫療保健系統結構的差異將決定照護現場設備的功能優先順序、部署策略和普及路徑。

區域需求促進因素和醫療保健系統結構導致全球即時心臟診斷設備（POC）的評估和採用路徑有顯著差異。在美洲，急診通訊協定和廣泛的門診病人網路推動了對可在醫院和門診診所部署的快速、整合式即時診斷解決方案的需求。該地區的醫療系統通常優先考慮與電子健康記錄的互通性和簡化的計費流程，從而影響產品功能需求和整合服務。

歐洲、中東和非洲不同的法規環境和實驗室基礎設施水準導致了不同的應用路徑。歐洲主要醫療中心的高級急診醫院優先考慮分析的嚴謹性和合規性，而中東和非洲部分地區資源有限、缺乏集中式實驗室的機構則正在採用即時檢測平台來擴大診斷能力。在這些地區，穩定性強、維護成本低、訓練資料清晰的設備將得到更廣泛的應用。

亞太地區正經歷著快速普及，這主要得益於急診設施的擴張、分散式醫療模式投資的增加以及對本地化生產和分銷的強烈需求。從大都會圈三級醫院到分散式社區診所，各種臨床環境都對高通量和攜帶式即時檢測（POC​​）解決方案產生了需求。根據不同地區，買家會尋求檢驗的臨床性能、可靠的供應鏈以及對改善患者就診流程和臨床決策的顯著貢獻，但這些標準的相對權重會因各地區醫療體系的優先事項和報銷框架而異。

競爭格局由現有企業、敏捷的創新者、策略夥伴關係以及不斷演進的服務模式所驅動，這些模式使產品性能與臨床結果保持一致。

心臟就地檢驗領域的競爭格局由傳統診斷設備製造商、照護現場專業公司和新興技術參與企業共同構成。市場現有企業利用與醫院和診所建立的穩固關係，提供廣泛的服務網路和豐富的監管經驗，從而促進醫院層面的採購和長期服務協議。這些公司通常透過投資平台互通性和擴展檢測專案功能來增強客戶維繫，從而支援在單一裝置中實現多種檢測策略。

即時檢測（POC​​）專家正積極尋求在急診醫學、農村醫療和院前救護急救等領域的細分市場應用機會，重點關注快速出結果和緊湊的儀器設計。產品開發的靈活性使得檢測方法和使用者介面能夠快速迭代，但拓展銷售和服務網路仍然是物流的重點。利用新型檢測化學技術和數位分析的參與企業帶來了競爭壓力，他們承諾提供更佳的分析效果和更好的使用者體驗，從而減輕培訓負擔並減少操作人員的差異。

隨著大型企業透過引入即時檢測（POC​​）能力來豐富其產品組合，以及創新者積極尋求通路准入和監管環境，策略夥伴關係和收購活動持續重塑著競爭格局。同時，試劑租賃、訂閱定價和基於結果的合約等服務模式也正在被探索，以使供應商的激勵機制與臨床影響保持一致。這些競爭措施將共同推動儀器性能、使用者獎勵和商業性靈活性的持續提升，從而惠及那些既需要可靠性又需要適應性的醫療保健系統。

醫療設備製造商和醫療系統可採取的切實可行的策略重點，以推動產品應用、降低供應風險並展現可衡量的臨床和營運價值。

產業領導者若想鞏固其在心臟即時檢測（POC​​）市場的地位，應優先考慮臨床證據的累積、模組化產品設計以及穩健的供應鏈策略。尤其引人注目的是，能夠將檢測與縮短住院時間、加快治療決策速度以及提高分診準確性聯繫起來的證據。同時，允許添加檢測項目和軟體升級的模組化平台，既有助於保護客戶的投資，又能幫助供應商有效率地擴展產品系列。

從營運角度來看，零件供應多元化和探索本地組裝方案可以降低關稅和物流方面的風險。與醫療系統採購團隊建立透明的關係，考慮整體擁有成本，並提供靈活的商業模式（例如分包和績效合約），可以降低採用門檻。從使用者體驗角度來看，簡化介面、減少維護需求並提供全面的訓練資源可以減少操作摩擦，並提高照護現場的資料品質。

最後，推行互通性標準並與電子健康記錄提供者合作，將有助於臨床工作流程的整合，並支持更廣泛的機構採用。透過結合臨床檢驗、靈活的商業化、彈性採購以及對以使用者為中心的設計的不懈關注，領導者可以最大限度地提高採用的可能性，並為醫護團隊和患者帶來可衡量的價值。

採用嚴謹的混合方法研究途徑，結合臨床醫師訪談、採購洞察、監管整合和多源三角驗證，以獲得可靠的策略資訊。

本分析所依據的研究採用了混合方法，以確保研究的深度、多方驗證和實用性。主要研究包括對急診和心臟監護室的臨床醫生、醫院和診所的採購負責人以及醫療器材製造商的產品經理進行結構化訪談。這些訪談揭示了實際工作流程需求、採購標準和器械功能優先級，提供了僅憑定量資料集無法捕捉到的細緻觀點。

二級研究整合了監管指南、臨床實踐指南和同行評審文獻，以確定生物標記的效用、預期設備性能以及診療路徑整合的現狀。技術趨勢和供應鏈發展方面的資訊來自行業簡報和公開的監管文件。在條件允許的情況下，我們透過比較一級和二級來源，識別一致的主題，並標記出存在分歧之處以便進行更深入的調查，從而對調查方法進行了交叉檢驗。

透過系統性的資料清理、質性訪談的主題編碼以及對研究結果的結構化綜合，確保了分析的嚴謹性，從而得出可操作的見解。品管步驟包括對解釋性結論的同行評審以及對技術聲明的專家驗證。最終形成了一份多方面的檢驗，旨在支持臨床、商業和營運領域的策略決策，其透明的方法論有助於結果的可重複性，並在需要更詳細資訊時進行有針對性的後續跟進。

整合臨床、技術和營運方面的必要因素，將決定哪些照護現場心臟技術能夠實現持續的臨床整合並產生影響。

總之，在技術進步、臨床對快速決策的需求以及不斷變化的採購重點的推動下，照護現場心臟診斷設備將在急診和分散式醫療模式中發揮日益重要的作用。最具影響力的設備將是那些兼具實驗室級性能、操作簡便性、強大的互通性和供應鏈韌性的設備。從製造商和經銷商到醫院領導和臨床醫生，價值鏈上的所有利益相關人員必須在證據生成、用戶體驗和商業性安排方面達成一致，才能充分發揮床邊心臟生物標記檢測的潛力。

隨著臨床環境持續將速度、準確性和成本效益置於優先地位，能夠實際改善患者就診流程和臨床療效的能力很可能推動其更廣泛應用。同時，地緣政治和政策發展將引發供應鏈的考量，企業必須透過多元化採購和在地化能力積極應對。展望未來，先進的檢測化學技術、智慧型裝置平台和以結果為導向的商業模式的融合，將定義心臟即時檢測（POC​​）下一階段的成長和整合。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

• 手持式即時檢測分析儀上靈敏的心臟生物標記檢測方法的快速發展，提高了心肌梗塞的早期檢出率。
• 在可攜式心臟即時檢測設備中採用人工智慧驅動的心電圖判讀模組，以實現高效的遠端分診
• 開發心臟衰竭和心肌梗塞綜合篩檢的肌鈣蛋白和利鈉肽綜合檢測平台
• 擴展智慧型手機整合式心臟即時檢測系統，以實現即時數據共用和遠端醫療連接。
• 實現用於心臟照護現場的微流體實驗室晶片平台，該平台具有超低樣本量和快速週轉的特點
• 加快對CLIA豁免的高靈敏度肌鈣蛋白檢測的監管，將推動其在門診和急診環境中的更廣泛應用。
• 心臟即時檢測設備製造商與遠端醫療提供者之間的策略合作，能夠提升分散式急性心臟照護的效率。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 心臟即時檢測設備市場（依產品類型分類）

• BNP
• CK-MB
• 肌紅蛋白
• 肌鈣蛋白
  • 肌鈣蛋白 I
  • 肌鈣蛋白T

第9章：依最終使用者分類的心臟即時檢測設備市場

• 診所
• 診斷實驗室
• 醫院
  • 心臟監護病房
  • 急診部

第10章：依技術分類的心臟即時檢測設備市場

• 比色分析
• 電化學
• 免疫檢測
  • 螢光
  • 側向流

第11章：以樣本類型分類的心臟即時檢測設備市場

• 電漿
• 血清
• 全血

第12章：心臟即時檢測設備市場（依應用領域分類）

• 急性冠狀動脈症候群
• 心臟衰竭

第13章：心臟即時偵測設備市場（依地區分類）

• 美洲
  • 北美洲
  • 拉丁美洲
• 歐洲、中東和非洲
  • 歐洲
  • 中東
  • 非洲
• 亞太地區

第14章：心臟即時檢測設備市場（依組別分類）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第15章：各國心臟即時檢測設備市場

• 美國
• 加拿大
• 墨西哥
• 巴西
• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 中國
• 印度
• 日本
• 澳洲
• 韓國

第16章 競爭格局

• 2024年市佔率分析
• FPNV定位矩陣，2024
• 競爭分析
  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories
  • Siemens Healthineers AG
  • Danaher Corporation
  • Becton Dickinson and Company
  • bioMerieux SA
  • Quidel Corporation
  • Nova Biomedical, Inc.
  • Trinity Biotech plc
  • Chembio Diagnostics Systems, Inc.

The Cardiac POC Testing Devices Market is projected to grow by USD 4.00 billion at a CAGR of 12.85% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 1.52 billion
Estimated Year [2025]	USD 1.69 billion
Forecast Year [2032]	USD 4.00 billion
CAGR (%)	12.85%

A concise yet compelling orientation to point-of-care cardiac diagnostics that frames clinical imperatives, operational priorities, and strategic adoption drivers

Point-of-care cardiac diagnostic devices have emerged as pivotal tools in modern cardiovascular care pathways, reshaping how clinicians detect and respond to acute cardiac events. These platforms deliver biomarker insights at or near the patient bedside, shortening diagnostic timelines and empowering quicker therapeutic decisions. The clinical priority for many providers is to reduce time-to-diagnosis for conditions such as acute coronary syndromes and heart failure exacerbations, and point-of-care solutions contribute directly to that objective by providing rapid, actionable results that integrate into emergency and inpatient workflows.

Operationally, hospitals and clinics value devices that balance analytical performance with ease of use, minimal maintenance, and seamless integration into electronic health records. Advances in assay chemistry and signal detection have improved sensitivity and specificity, which in turn increases clinician confidence in point-of-care results. As a result, adoption is increasingly driven by a combination of clinical utility, workflow compatibility, and total cost of ownership considerations. When stakeholders evaluate strategic investments in cardiac point-of-care technologies, they weigh not only diagnostic accuracy but also device footprint, consumable logistics, staff training requirements, and regulatory pathways that affect long-term operational viability.

Taken together, these factors frame the business case for point-of-care cardiac devices: they are instruments of clinical acceleration and systems efficiency. Moving forward, the ability of manufacturers and health systems to align product design with clinical requirements and reimbursement realities will determine which platforms become standard fixtures in acute care and ambulatory settings.

How technological advances, clinical workflow redesign, and evolving reimbursement expectations are jointly transforming adoption and utility of cardiac point-of-care diagnostics

The landscape of cardiac point-of-care testing is undergoing transformative shifts driven by technological innovation, changing care models, and heightened expectations for rapid diagnostic precision. On the technology front, miniaturization of assay components, integration of electrochemical and optical detection systems, and refinement of immunoassay formats have collectively improved analytical performance while reducing time-to-result. These developments expand the clinical contexts where point-of-care testing can be reliably deployed, including pre-hospital triage and resource-constrained clinic environments.

Concurrently, care delivery paradigms are evolving; emergency departments and cardiac care units increasingly rely on faster diagnostic information to prioritize patients and manage bed flow. This clinical pressure, coupled with a broader move toward decentralized care, elevates demand for robust point-of-care platforms that deliver laboratory-grade results without the delays associated with central labs. Meanwhile, payers and health systems are scrutinizing value, favoring solutions that demonstrably reduce downstream costs through earlier intervention and reduced admissions. The cumulative effect is a shift from early adopter experimentation to mainstream clinical integration.

Regulatory and reimbursement frameworks are also adapting, with agencies clarifying performance expectations for near-patient devices and payers refining coverage policies that reflect clinical evidence. As a result, manufacturers that can demonstrate consistent analytical validity, operational resilience, and measurable clinical impact will secure stronger uptake. In summary, technological advancement, clinical workflow redesign, and economic accountability are converging to transform how cardiac point-of-care diagnostics contribute to faster, more effective care.

Assessment of 2025 tariff-driven supply-chain pressures and strategic sourcing responses shaping device availability, procurement economics, and operational continuity

Trade policy developments, including tariff adjustments introduced in the United States in 2025, have created a new set of considerations for manufacturers, distributors, and healthcare purchasers in the cardiac point-of-care ecosystem. Tariffs influence component sourcing, pricing strategies, and supply-chain resilience, prompting manufacturers to reassess procurement footprints and to explore alternative manufacturing locations or supplier partnerships. In response, many firms have initiated supply-chain diversification efforts to mitigate single-country exposure and to preserve margin structures without compromising clinical performance.

These tariff-driven pressures also affect distribution economics. Distributors and hospital procurement teams are recalibrating contract terms and inventory strategies to accommodate potential cost variability. For some vendors, the tariff environment accelerated plans to localize assembly or to secure long-term component agreements, which helps stabilize unit costs and shortens replenishment cycles. Additionally, tariff impacts have prompted closer scrutiny of input cost breakdowns and encouraged transparency between suppliers and customers so that adjustments can be anticipated rather than reacted to.

From a clinical operations perspective, the specter of elevated costs has encouraged health systems to prioritize devices that offer clear workflow efficiencies and that reduce downstream resource utilization, such as shorter emergency department stays or fewer unnecessary admissions. Ultimately, tariffs serve as a catalyst for strategic supply-chain planning, compelling stakeholders to balance cost containment with uninterrupted access to high-quality diagnostics and to consider operational levers that sustain clinical capacity while absorbing economic shifts.

A comprehensive segmentation analysis highlighting biomarker selection, end-user workflow demands, detection technologies, sample preferences, and primary cardiac applications

A nuanced segmentation of the cardiac point-of-care testing market reveals distinct product, end-user, technological, sample-type, and application dynamics that collectively shape demand and development priorities. Product differentiation centers on biomarkers such as BNP, CK-MB, Myoglobin, and the troponins, with troponin assays further divided into Troponin I and Troponin T. Troponin-based testing remains central to acute chest pain pathways given its diagnostic specificity for myocardial injury, while BNP assays are prioritized in heart failure assessment scenarios. CK-MB and myoglobin retain utility in certain contexts where complementary information or historical comparison is clinically useful.

End-user segmentation spans clinics, diagnostic laboratories, and hospitals, the latter encompassing both cardiac care units and emergency departments. Emergency settings prioritize speed and ruggedized workflows, whereas cardiac care units emphasize serial measurement capabilities and integration with continuous monitoring systems. Clinics and outpatient centers value compact, low-maintenance devices that facilitate triage and follow-up without heavy laboratory overhead. Diagnostic laboratories that adopt point-of-care platforms often do so to offload high-throughput analyzers during peak demand or to extend services to satellite sites.

Technological differentiation includes colorimetric, electrochemical, and immunoassay approaches, with immunoassays further divided into fluorescence-based and lateral flow formats. Colorimetric methods offer simplicity and cost advantages for certain analytes, electrochemical platforms excel in miniaturized, low-power architectures, and immunoassays deliver the sensitivity required for low-abundance cardiac biomarkers. Sample-type considerations cover plasma, serum, and whole blood; whole blood compatibility increases usability at the bedside by eliminating centrifugation steps, while plasma and serum samples are preferred when laboratory integration and standardized processing are required. Application-wise, devices are developed primarily for acute coronary syndrome and heart failure use cases, each imposing different sensitivity, turnaround time, and longitudinal monitoring requirements. Understanding these segmentation layers allows stakeholders to align product design, clinical validation, and commercialization strategies with the operational realities of intended end users.

Regional demand and health-system architecture differences that dictate point-of-care device feature priorities, deployment strategies, and adoption pathways across global territories

Regional demand drivers and health-system architectures create meaningful variation in how point-of-care cardiac diagnostics are evaluated and implemented across global geographies. In the Americas, emergency care protocols and extensive outpatient networks drive demand for rapid, integrated point-of-care solutions that can be deployed across hospitals and ambulatory clinics. Health systems in this region often emphasize interoperability with electronic health records and streamlined billing practices, which shapes product feature requirements and integration services.

In Europe, Middle East & Africa, heterogeneous regulatory environments and varying levels of laboratory infrastructure produce a diverse set of adoption pathways. High-acuity hospitals in major European centers prioritize analytical rigor and regulatory compliance, whereas resource-limited settings in parts of the Middle East and Africa adopt point-of-care platforms to extend diagnostic capacity where centralized laboratories are scarce. In these contexts, devices that combine robustness, minimal maintenance, and clear training materials achieve broader traction.

The Asia-Pacific region demonstrates rapid uptake driven by expanding acute care facilities, growing investment in decentralized care models, and strong interest in localization of manufacturing and distribution. Diverse clinical settings-from metropolitan tertiary hospitals to decentralized community clinics-create demand for both high-throughput and handheld point-of-care solutions. Across regions, purchasers look for validated clinical performance, reliable supply chains, and demonstrable contributions to improved patient flow and clinical decision-making, but the relative weighting of these criteria varies based on local health-system priorities and reimbursement frameworks.

Competitive landscape dynamics driven by incumbents, agile innovators, strategic partnerships, and evolving service models that align product performance with clinical outcomes

Competitive dynamics in the cardiac point-of-care testing sector are shaped by a mix of legacy diagnostic manufacturers, specialized point-of-care firms, and emerging technology entrants. Market incumbents leverage established relationships with hospitals and clinics, providing broad service networks and deep regulatory experience that facilitate hospital-level procurement and long-term service agreements. These organizations often invest in platform interoperability and extended menu capabilities to reinforce customer retention and to support multi-assay strategies within a single device footprint.

Specialized point-of-care firms focus on speed-to-result and compact device design, pursuing niche adoption opportunities in emergency medicine, rural healthcare, and pre-hospital care. Their agility in product development enables rapid iteration on assay formats and user interfaces, although scaling distribution and service networks remains a logistical focus. New entrants leveraging novel detection chemistries or digital analytics introduce competitive pressure by promising either analytical improvements or enhanced user experiences that reduce training burdens and operator variability.

Strategic partnerships and acquisition activity continue to shape the competitive landscape as larger firms supplement portfolios with point-of-care capabilities and as innovators seek channel access and regulatory expertise. In parallel, service models such as reagent leasing, subscription pricing, or outcome-based contracts are being explored to align vendor incentives with clinical impact. Collectively, these competitive behaviors drive continuous improvement in device performance, user experience, and commercial flexibility, benefitting health systems that require both reliability and adaptability.

Actionable strategic priorities for device makers and health systems to enhance adoption, mitigate supply risks, and demonstrate measurable clinical and operational value

Industry leaders seeking to strengthen their position in the cardiac point-of-care market should prioritize a combination of clinical evidence generation, modular product design, and resilient supply-chain strategies. Investing in robust clinical validation studies that demonstrate real-world impact on patient pathways will accelerate adoption by hospitals and payers; evidence that links testing to reduced length of stay, faster therapeutic decisions, or improved triage accuracy is particularly persuasive. Concurrently, modular platforms that allow incremental assay additions and software upgrades help customers protect their investment while enabling vendors to scale product portfolios efficiently.

On the operational side, diversifying component supply and considering regional assembly options will mitigate tariff and logistics-related vulnerabilities. Transparent engagement with health-system procurement teams to align total cost of ownership considerations and to offer flexible commercial models-such as reagent-as-a-service or outcome-linked contracts-can lower adoption barriers. From a user experience perspective, simplifying interfaces, minimizing maintenance needs, and providing comprehensive training resources will reduce operational friction and improve data quality at the point of care.

Finally, pursuing interoperability standards and partnering with electronic health record providers enhances clinical workflow integration and supports broader institutional adoption. By combining clinical validation, flexible commercialization, resilient sourcing, and a relentless focus on user-centered design, leaders can maximize adoption potential and deliver measurable value to care teams and patients alike.

A rigorous mixed-methods research approach combining clinician interviews, procurement insights, regulatory synthesis, and multi-source triangulation for reliable strategic intelligence

The research underpinning this analysis employed a mixed-methods approach to ensure depth, triangulation, and practical relevance. Primary research included structured interviews with clinicians from emergency departments and cardiac care units, procurement leaders from hospitals and clinics, and product managers across device manufacturers. These conversations illuminated real-world workflow needs, procurement criteria, and device feature priorities, offering nuanced perspectives that quantitative datasets alone cannot capture.

Secondary research synthesized regulatory guidance, clinical practice guidelines, and peer-reviewed literature to contextualize biomarker utility, device performance expectations, and care-pathway integration. Information on technology trends and supply-chain developments was corroborated through industry briefings and publicly available regulatory filings. Where possible, methodology cross-validation was achieved by comparing primary insights with secondary sources to identify consistent themes and to flag divergent viewpoints for deeper inquiry.

Analytical rigor was maintained through systematic data cleaning, thematic coding of qualitative interviews, and structured synthesis of findings to produce actionable insights. Quality control steps included peer review of interpretive conclusions and verification of technical claims with subject-matter experts. The result is a multi-perspective assessment designed to support strategic decisions across clinical, commercial, and operational domains, with transparent methods that facilitate reproducibility and targeted follow-up research when deeper granularity is required.

Synthesis of clinical, technological, and operational imperatives that will determine which point-of-care cardiac technologies achieve sustained clinical integration and impact

In conclusion, point-of-care cardiac diagnostics are positioned to play an increasingly central role in acute care and decentralized care models, driven by technological progress, clinical need for rapid decision-making, and evolving procurement priorities. The most impactful devices will be those that pair laboratory-quality performance with operational simplicity, robust interoperability, and supply-chain resilience. Stakeholders across the value chain-from manufacturers and distributors to hospital leaders and clinicians-must align on evidence generation, user experience, and commercial arrangements to realize the full potential of bedside cardiac biomarker testing.

As clinical environments continue to prioritize speed, accuracy, and cost-effectiveness, the ability to demonstrate tangible improvements in patient flow and clinical outcomes will be a decisive factor in broader adoption. Simultaneously, geopolitical and policy developments introduce supply-chain considerations that organizations must proactively address through diversified sourcing and localized capabilities. Looking ahead, the intersection of refined assay chemistries, intelligent device platforms, and outcome-oriented commercial models will define the next phase of growth and integration for cardiac point-of-care testing.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Rapid evolution of high-sensitivity cardiac biomarker assays in handheld POC analyzers to improve early MI detection
• 5.2. Adoption of AI-driven ECG interpretation modules in portable cardiac POC devices for efficient remote triage
• 5.3. Development of integrated troponin and natriuretic peptide detection platforms for comprehensive heart failure and myocardial infarction screening
• 5.4. Expansion of smartphone-integrated cardiac POC testing systems enabling real-time data sharing and telemedicine connectivity
• 5.5. Implementation of microfluidic lab-on-a-chip platforms in cardiac point-of-care assays for ultra-low sample volumes and accelerated turnaround
• 5.6. Regulatory acceleration of CLIA-waived high-sensitivity troponin tests facilitating wider adoption in outpatient and emergency settings
• 5.7. Strategic collaborations between cardiac POC device manufacturers and telehealth providers to enhance decentralized acute cardiac care delivery

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cardiac POC Testing Devices Market, by Product Type

• 8.1. BNP
• 8.2. CK-MB
• 8.3. Myoglobin
• 8.4. Troponin
  • 8.4.1. Troponin I
  • 8.4.2. Troponin T

9. Cardiac POC Testing Devices Market, by End User

• 9.1. Clinics
• 9.2. Diagnostic Laboratories
• 9.3. Hospital
  • 9.3.1. Cardiac Care Unit
  • 9.3.2. Emergency Department

10. Cardiac POC Testing Devices Market, by Technology

• 10.1. Colorimetric
• 10.2. Electrochemical
• 10.3. Immunoassay
  • 10.3.1. Fluorescence
  • 10.3.2. Lateral Flow

11. Cardiac POC Testing Devices Market, by Sample Type

• 11.1. Plasma
• 11.2. Serum
• 11.3. Whole Blood

12. Cardiac POC Testing Devices Market, by Application

• 12.1. Acute Coronary Syndrome
• 12.2. Heart Failure

13. Cardiac POC Testing Devices Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Cardiac POC Testing Devices Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Cardiac POC Testing Devices Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. F. Hoffmann-La Roche Ltd
  • 16.3.2. Abbott Laboratories
  • 16.3.3. Siemens Healthineers AG
  • 16.3.4. Danaher Corporation
  • 16.3.5. Becton Dickinson and Company
  • 16.3.6. bioMerieux SA
  • 16.3.7. Quidel Corporation
  • 16.3.8. Nova Biomedical, Inc.
  • 16.3.9. Trinity Biotech plc
  • 16.3.10. Chembio Diagnostics Systems, Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. CARDIAC POC TESTING DEVICES MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. CARDIAC POC TESTING DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. CARDIAC POC TESTING DEVICES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY BNP, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY BNP, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY BNP, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY BNP, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY BNP, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY BNP, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CK-MB, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CK-MB, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CK-MB, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CK-MB, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CK-MB, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CK-MB, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY MYOGLOBIN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY MYOGLOBIN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY MYOGLOBIN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY MYOGLOBIN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY MYOGLOBIN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY MYOGLOBIN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN I, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN I, BY REGION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN I, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN I, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN I, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN I, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN T, BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN T, BY REGION, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN T, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN T, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN T, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN T, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CARDIAC CARE UNIT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CARDIAC CARE UNIT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CARDIAC CARE UNIT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CARDIAC CARE UNIT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CARDIAC CARE UNIT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY CARDIAC CARE UNIT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY EMERGENCY DEPARTMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY EMERGENCY DEPARTMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY EMERGENCY DEPARTMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY EMERGENCY DEPARTMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY EMERGENCY DEPARTMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY EMERGENCY DEPARTMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY COLORIMETRIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY COLORIMETRIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY COLORIMETRIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY COLORIMETRIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY COLORIMETRIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY COLORIMETRIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY ELECTROCHEMICAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY ELECTROCHEMICAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY ELECTROCHEMICAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY ELECTROCHEMICAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY ELECTROCHEMICAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY ELECTROCHEMICAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY FLUORESCENCE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY FLUORESCENCE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY FLUORESCENCE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY FLUORESCENCE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY FLUORESCENCE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY FLUORESCENCE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY LATERAL FLOW, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY LATERAL FLOW, BY REGION, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY LATERAL FLOW, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY LATERAL FLOW, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY LATERAL FLOW, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY LATERAL FLOW, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY PLASMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY PLASMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY PLASMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY PLASMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY SERUM, BY REGION, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY SERUM, BY REGION, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY SERUM, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY SERUM, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY SERUM, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY REGION, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY REGION, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY HEART FAILURE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY HEART FAILURE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 149. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 150. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 151. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 152. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 153. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2024 (USD MILLION)
• TABLE 154. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2025-2032 (USD MILLION)
• TABLE 155. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 156. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 157. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
• TABLE 158. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2025-2032 (USD MILLION)
• TABLE 159. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 160. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 161. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
• TABLE 162. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
• TABLE 163. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 164. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 165. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 166. AMERICAS CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 167. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 168. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 169. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 170. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 171. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2024 (USD MILLION)
• TABLE 172. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2025-2032 (USD MILLION)
• TABLE 173. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 174. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 175. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
• TABLE 176. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2025-2032 (USD MILLION)
• TABLE 177. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 178. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 179. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
• TABLE 180. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
• TABLE 181. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 182. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 183. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 184. NORTH AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 185. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 186. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 187. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 188. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 189. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2024 (USD MILLION)
• TABLE 190. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2025-2032 (USD MILLION)
• TABLE 191. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 192. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 193. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
• TABLE 194. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2025-2032 (USD MILLION)
• TABLE 195. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 196. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 197. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
• TABLE 198. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
• TABLE 199. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 200. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 201. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 202. LATIN AMERICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 204. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 205. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 206. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 207. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2024 (USD MILLION)
• TABLE 208. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2025-2032 (USD MILLION)
• TABLE 209. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 210. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 211. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
• TABLE 212. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2025-2032 (USD MILLION)
• TABLE 213. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 214. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 215. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
• TABLE 216. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
• TABLE 217. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 218. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 219. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 220. EUROPE, MIDDLE EAST & AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 221. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 222. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 223. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 224. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 225. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2024 (USD MILLION)
• TABLE 226. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2025-2032 (USD MILLION)
• TABLE 227. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 228. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 229. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
• TABLE 230. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2025-2032 (USD MILLION)
• TABLE 231. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 232. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 233. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
• TABLE 234. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
• TABLE 235. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 236. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 237. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 238. EUROPE CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 239. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 240. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 241. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 242. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 243. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2024 (USD MILLION)
• TABLE 244. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2025-2032 (USD MILLION)
• TABLE 245. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 246. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 247. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
• TABLE 248. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2025-2032 (USD MILLION)
• TABLE 249. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 250. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 251. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
• TABLE 252. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
• TABLE 253. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 254. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 255. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 256. MIDDLE EAST CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 257. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 258. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 259. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 260. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 261. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2024 (USD MILLION)
• TABLE 262. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2025-2032 (USD MILLION)
• TABLE 263. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 264. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 265. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
• TABLE 266. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2025-2032 (USD MILLION)
• TABLE 267. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 268. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 269. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
• TABLE 270. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
• TABLE 271. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 272. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 273. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 274. AFRICA CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 275. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 276. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 277. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 278. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 279. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2024 (USD MILLION)
• TABLE 280. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2025-2032 (USD MILLION)
• TABLE 281. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 282. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 283. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
• TABLE 284. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2025-2032 (USD MILLION)
• TABLE 285. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 286. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 287. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
• TABLE 288. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
• TABLE 289. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 290. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 291. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 292. ASIA-PACIFIC CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 293. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 294. GLOBAL CARDIAC POC TESTING DEVICES MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 295. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 296. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 297. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 298. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 299. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2018-2024 (USD MILLION)
• TABLE 300. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY TROPONIN, 2025-2032 (USD MILLION)
• TABLE 301. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 302. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 303. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
• TABLE 304. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY HOSPITAL, 2025-2032 (USD MILLION)
• TABLE 305. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 306. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 307. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
• TABLE 308. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
• TABLE 309. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 310. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
• TABLE 311. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 312. ASEAN CARDIAC POC TESTING DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 313. GCC CARDIAC POC TESTING DEVICES MARKET